BN 82451
Alternative Names: BN-82451B; BN82451Latest Information Update: 05 Nov 2023
At a glance
- Originator Ipsen
- Class Amines; Neuroprotectants; Phenols; Small molecules; Thiazoles
- Mechanism of Action Lipid peroxidation inhibitors; Monoamine oxidase B inhibitors; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Huntington's disease
- Discontinued Amyotrophic lateral sclerosis; Parkinson's disease
Most Recent Events
- 31 May 2016 Ipsen completes enrolment in its phase II trial for Huntington's disease in Germany (NCT02231580)
- 01 Sep 2014 Phase-II clinical trials in Huntington's disease in Germany (PO)
- 26 Nov 2013 Phase-II clinical trials in Huntington's disease in France (unspecified route)